Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 05, 2023 08:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
June 28, 2023 11:36 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech 宣布在《美国癌症研究杂志》上发表一项评估 Ampligen® 治疗胰腺癌的临床前研究取得的积极结果。

佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布发表临床前数据，数据表明 Ampligen 有可能直接作用于肿瘤细胞，抑制肿瘤细胞在肿瘤 TLR-3 水平足够的胰腺癌患者中的生长，这意味着有种潜在的生物标志物可识别出可能对...
June 27, 2023 12:49 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech 宣布获得荷兰主管机构和伦理委员会的批准，开始一项评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi (durvalumab) 联合治疗胰腺癌的 1b/2 期研究

Ampligen 已显示出检查点抑制剂的治疗协同作用，具有提高存活率与疗效的潜力。患者入组预计于 2023 年底前开始佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布已获得荷兰的所需批准，Erasmus...
June 27, 2023 11:16 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3...
June 27, 2023 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla.,...
June 14, 2023 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
June 12, 2023 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the...
May 15, 2023 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
May 09, 2023 08:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
April 12, 2023 08:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM...